The Hydration Pharmaceuticals Company Ltd (HPC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, The Hydration Pharmaceuticals Company Ltd (HPC) has a cash flow conversion efficiency ratio of -0.606x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.64 Million ≈ $-1.16 Million USD) by net assets (AU$2.71 Million ≈ $1.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see The Hydration Pharmaceuticals Company Lt (HPC) market capitalisation for the company's overall valuation and market capitalisation.
The Hydration Pharmaceuticals Company Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how The Hydration Pharmaceuticals Company Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
The Hydration Pharmaceuticals Company Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of The Hydration Pharmaceuticals Company Ltd ranked by their cash flow conversion efficiency. Explore HPC cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aker Horizons AS
OL:AKH
|
-0.007x |
|
SPOTLITE360 IOT SOLUTIONS
F:87A0
|
N/A |
|
Tarku Resources Ltd
V:TKU
|
-0.015x |
|
Ribbon Acquisition Corp Rights
NASDAQ:RIBBR
|
N/A |
|
Geneuro SA
PA:GNRO
|
0.393x |
|
Prostatype Genomics AB
ST:PROGEN
|
-0.234x |
|
Tessin Nordic Holding AB
ST:TESSIN
|
0.101x |
|
Made Tech Group PLC
LSE:MTEC
|
0.132x |
Annual Cash Flow Conversion Efficiency for The Hydration Pharmaceuticals Company Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of The Hydration Pharmaceuticals Company Ltd from 2018 to 2024. View HPC live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$2.74 Million ≈ $1.94 Million |
AU$-3.02 Million ≈ $-2.14 Million |
-1.101x | -106.89% |
| 2023-12-31 | AU$-358.25K ≈ $-253.49K |
AU$-5.73 Million ≈ $-4.05 Million |
15.993x | +752.93% |
| 2022-12-31 | AU$3.98 Million ≈ $2.82 Million |
AU$-9.75 Million ≈ $-6.90 Million |
-2.449x | -301.06% |
| 2021-12-31 | AU$13.23 Million ≈ $9.36 Million |
AU$-8.08 Million ≈ $-5.72 Million |
-0.611x | +68.33% |
| 2020-12-31 | AU$2.00 Million ≈ $1.42 Million |
AU$-3.86 Million ≈ $-2.73 Million |
-1.928x | -69.48% |
| 2019-12-31 | AU$2.44 Million ≈ $1.73 Million |
AU$-2.78 Million ≈ $-1.97 Million |
-1.138x | +43.84% |
| 2018-12-31 | AU$2.66 Million ≈ $1.88 Million |
AU$-5.40 Million ≈ $-3.82 Million |
-2.026x | -- |
About The Hydration Pharmaceuticals Company Ltd
The Hydration Pharmaceuticals Company Limited, together with its subsidiaries, markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, Canada, and the United States. The company sells its products under the Hydralyte brand through retail stores and online. The Hydration Pharmaceuticals Company Limited was founded in 2001 and is based in Melbourne, Australi… Read more